TL;DR
This paper introduces a novel method for visualizing tumors by detecting chemiluminescence (CL) generated by a photosensitizer and a specific CL probe. This technique leverages the fact that photosensitizers produce reactive oxygen species (ROS), particularly singlet oxygen (¹O₂), within tumors, which can then be detected by the probe, allowing for tumor localization.
What Problem Does This Paper Address?
Photodynamic therapy (PDT) is a promising cancer treatment that relies on photosensitizers accumulating in tumors and generating cytotoxic ROS upon light activation. However, precisely locating these tumors and understanding the ROS dynamics within them remains a challenge. Current methods for visualizing tumor-specific ROS generation are limited. This paper addresses this gap by proposing a chemiluminescence-based imaging technique that can visualize ¹O₂ generation specifically within tumors, offering a potential new tool for tumor diagnosis and localization.
Methods
The core of this research is the development and application of a photosensitized chemiluminescence (CL) imaging system. The key components are:
- Photosensitizer: Hematoporphyrin derivative (HpD) was chosen for its known accumulation in malignant tissues.
- Chemiluminescence Probe: A novel probe, 3,7-dihydro-6-{4-{2-(N'-(5-fluoresceinyl)thioureido)ethoxy}phenyl}-2-methylimidazo{1,2-a}pyrazin-3-one dosium salt (FCLA), was used. FCLA is highly sensitive and specific for singlet oxygen (¹O₂) and superoxide (O₂⁻), and importantly, it emits light at a relatively short wavelength (532 nm).
- Imaging System: A custom-built setup featuring an intensified charge-coupled device (ICCD) detector, a high-aperture photographic lens, and a light-tight box was employed. This system is designed to capture weak CL signals.
- Experimental Procedure:
- In vitro: Model solutions containing HpD, a serum albumin (HSA) to mimic biological conditions, and FCLA were irradiated. The CL signal was measured after a short delay (2 seconds) post-irradiation to avoid interference from scattered light or fluorescence.
- In vivo: Tumor-bearing nude mice were injected with HpD, followed by FCLA. After allowing for diffusion, the mice were irradiated, and the resulting CL was imaged.
- ROS Confirmation: To confirm that the CL signal originated from ¹O₂, experiments involved using ROS quenchers (like sodium azide for ¹O₂) and deuterium oxide (D₂O) to enhance ¹O₂ lifetime.
Datasets
Not discussed in the paper. The experiments were conducted using model solutions and in vivo studies with tumor-bearing nude mice.
Key Insights and Ideas
- FCLA as a ¹O₂ Reporter: The study successfully demonstrates that FCLA can act as a sensitive and specific reporter for ¹O₂ generated during photosensitization.
- ¹O₂ as the Primary ROS: Experiments with quenchers strongly suggest that ¹O₂ is the dominant reactive oxygen species responsible for the observed chemiluminescence in this photosensitization process, rather than O₂⁻ or OH radicals.
- In Vivo Tumor Visualization: The most significant insight is the successful imaging of tumors in live mice using this photosensitized CL method. The CL signal was localized to the tumor region, indicating the potential for this technique as a diagnostic tool.
- Conversion of Light Wavelengths: The method converts longer wavelength irradiation light (>550 nm) into shorter wavelength CL (532 nm), which is advantageous for avoiding autofluorescence interference.
Key Results
- Model Solution CL: The model solution containing HpD, HSA, and FCLA exhibited significant light emission after irradiation, which attenuated over time.
- Quencher Effects: Sodium azide (NaN₃), a ¹O₂ quencher, significantly inhibited the CL signal (by ~71.5%), supporting the role of ¹O₂. Deuterium oxide (D₂O) enhanced the CL signal (by ~35.1%), consistent with increased ¹O₂ lifetime. Other quenchers (SOD, mannitol, catalase) had less significant effects.
- In Vivo Imaging: A clear CL image of the tumor was obtained in tumor-bearing nude mice. The luminescent area precisely corresponded to the tumor location.
- Signal-to-Background Ratio: The in vivo experiments achieved a signal-to-background ratio of 1.37 ± 0.12.
- Control Experiments: Mice treated with only HpD or only FCLA showed no detectable light emission, confirming the necessity of both components and the photosensitization process.
Limitations and Future Work
- Tissue Penetration Depth: The authors acknowledge that the current method is limited to detecting emissions from superficial tumors due to the short emission wavelength of FCLA (532 nm), which has poor penetration in biological tissues.
- Future Directions: The paper suggests that this novel photosensitization localization method holds potential for clinical tumor diagnosis. Future work would likely focus on developing longer-wavelength emitting CL probes or alternative imaging modalities to overcome the penetration depth limitation, enabling the detection of deeper tumors.
Summary updated